Difference between revisions of "Olanzapine LA-Olanzapine"
From Psychiatrienet
| Line 6: | Line 6: | ||
| info = {{caveQT}} | | info = {{caveQT}} | ||
| view = StopDepotStartOral.jpg | | view = StopDepotStartOral.jpg | ||
| + | }} | ||
| + | |||
| + | {{Drugswitch | ||
| + | | from = Olanzapine_LA | ||
| + | | to = Olanzapine<ref> A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2 </ref> | ||
| + | | stop = {{Lastinjection}} | ||
| + | | start = {{StartOral afterDepot}} | ||
| + | | info = {{caveQT}} | ||
| + | * the T<sub>1/2</sub> of olanzapine depot is approximately 30 days.<ref> KNMP Kennisbank, informatorium medicamentorum: Olanzapine</ref> | ||
| + | |||
}} | }} | ||
Revision as of 15:02, 8 March 2024
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
Switch medication from Olanzapine_LA to Olanzapine.[4] [5]
Stop Olanzapine_LA - Day 1: Last depot injection
Start Olanzapine- Week 1-3: approx. 25% of target dose
- Week 4-6: approx. 50% of target dose
- Week 7-9: approx. 75% of target dose
- Week 10: target dose
More information- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[6]
— Olanzapine_LA — Olanzapine
- ↑ 1.0 1.1 1.2 1.3 KNMP; Informatorium Medicamentorum 2023; Monografie "olanzapine" (Dutch)
- ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
| ||||||||||||||||||||||||
| {{:Olanzapine[1] }} | ||||||||||||||||||||||||
Switch medication from Olanzapine_LA to Olanzapine[1].[2] [3]
Stop Olanzapine_LA - Day 1: Last depot injection
Start Olanzapine[1]- t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
- t= 1 x T1/2 of depot approx. 50% of target dose
- t= 2 x T1/2 of depot approx. 75% of target dose
- t= 3 x T1/2 of depot approx. 100% of target dose
- See 'more information' for the T1/2 of this depot
More information- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[4]
- the T1/2 of olanzapine depot is approximately 30 days.[5]
- ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
- ↑ KNMP Kennisbank, informatorium medicamentorum: Olanzapine
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
[[Category:SwitchOlanzapine[1]]]
